Back A A A Font Size Receive E-mail Alerts Press Releases

Tubridge® Gains CFDA Approval


Shanghai, China – MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech"), a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), recently gained the approval of China Food and Drug Administration ("CFDA") for its in-house developed Tubridge® Vascular Reconstruction Device ("Tubridge®"). It is the fifth product of MicroPort® that obtained the CFDA approval through Green-Path, a fast-track approval process offered by CFDA for innovative medical devices.
Tubridge® is the first China-developed flow diverting stent that has obtained CFDA approval in China. It is designed for the treatment of large and giant cerebral aneurysm. The device cures the cerebral aneurysm by effectively diverting the blood flow based on the hemodynamics, reducing the impact of blood flow to the cerebral aneurysm, and enabling the endothelial cells to grow along the stent struts and gradually repair aneurysmal neck.
Since the release of the results of International Subarachnoid Aneurysm Trial in 2002, interventional treatment has experienced rapid development and has become one of the major treatment methods of intracranial aneurysm. However, when it comes to treating large and giant cerebral aneurysm, traditional stent-assisted coil embolization technique has its limitations such as complex procedure, mass effect and high reoccurrence rate.
In 2005, MicroPort® started to develop Tubridge® and successfully broke many technological hurdles such as densely meshed wire braids. Tubridge® was selected as one of the projects in the National Key Technology R&D Program for China's 12th Five-Year Plan. It is also the first flow diverting stent used in the clinical setting, researched via a hemodynamic approach, and studied in a randomized clinical trial, as well as the first neurovascular device obtained CFDA Green-Path status in China.
A cerebral aneurysm is a weak or thin spot on a blood vessel in the brain that balloons up and fills with blood. It is the main cause of subarachnoid hemorrhage, and is the third top killer among acute cerebrovascular diseases, after acute ischemic stroke and hypertensive cerebral hemorrhage. The bulging aneurysm can put pressure on a nerve or surrounding brain tissue. Aneurysms can later burst and bleed into the brain, causing serious complications or even death. Large and giant aneurysms are the most dangerous, with high aneurysmal rupture rate, high treatment cost, complex operating procedure and high recurrence rate. The CFDA approval of Tubridge® will definitely enable more domestic intracranial aneurysm patients to benefit from this innovative technology.
Zhiyong Xie President of MicroPort® NeuroTech said: "MicroPort® NeuroTech is dedicated to developing innovative solutions for cerebrovascular diseases. We will provide high quality medical devices by constant innovation to benefit patients with cerebrovascular disease."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® EP Attends the 10th VAS-CHINA
[Next]:MPSC Announces 2017 Annual Results